CAR-T cell therapy is accelerating in Shanghai, providing international patients with a new treatment option. As one of China's most active cities for medical technology innovation, Shanghai has multiple medical institutions carrying out CAR-T treatment, with cost advantages compared with Europe and the US, and increasingly complete supporting services.
CAR-T treatment resources in Shanghai
Shanghai has multiple hematology-oncology centers with CAR-T treatment capability, covering the full process from cell manufacturing, bridging therapy to post-infusion management (such as cytokine release syndrome management). Multiple CAR-T products have been approved in China for indications including relapsed/refractory lymphoma and multiple myeloma.
Treatment cost and value
After CAR-T products were approved in China, costs have gradually decreased from the initially high prices, and some products have entered medical insurance negotiation catalogs, reducing patients' actual burden. Compared with the hundreds of thousands of dollars often charged in Europe and the US, treatment in China has a significant price advantage.
Treatment process for international patients
International patients traveling to Shanghai for CAR-T treatment usually go through: initial medical record review, remote expert consultation, in-person evaluation and cell collection, bridging therapy during cell manufacturing, infusion and inpatient observation, and post-discharge follow-up. The whole process usually takes several weeks, and patients should plan their time well.
MedBridge services
MedBridge can connect international patients with CAR-T treatment centers in Shanghai, providing medical record evaluation, expert consultation arrangements, treatment cost estimation and full coordination services.